Viewing Study NCT04500717



Ignite Creation Date: 2024-05-06 @ 3:03 PM
Last Modification Date: 2024-10-26 @ 1:41 PM
Study NCT ID: NCT04500717
Status: UNKNOWN
Last Update Posted: 2020-08-05
First Post: 2020-08-02

Brief Title: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
Sponsor: Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization: Cancer Institute and Hospital Chinese Academy of Medical Sciences

Study Overview

Official Title: Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Locally Advanced Or Metastatic NSCLC Patients With Concomitant EGFR and Tumor Suppressor Gene Mutation A Multicenter Open-Label Randomized Controlled Phase III Study ACROSS2
Status: UNKNOWN
Status Verified Date: 2020-07
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ACROSS2
Brief Summary: This is a multicenter randomized controlled phase III study
Detailed Description: Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Locally Advanced Or Metastatic NSCLC Patients With Concomitant EGFR and Tumor Suppressor Gene Mutation A Multicenter Open-Label Randomized Controlled Phase III Study ACROSS2

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None